Ingrezza Sprinkle — Medical Mutual
Chorea associated with Huntington’s Disease - Initial Therapy
Initial criteria
- Patient is age ≥ 18 years; AND
- Diagnosis of Huntington’s Disease is confirmed by genetic testing (for example, an expanded HTT CAG repeat sequence of at least 36); AND
- Ingrezza is prescribed by or in consultation with a neurologist or psychiatrist; AND
- Patient has tried a tetrabenazine product (generic tetrabenazine or brand Xenazine) and has demonstrated inadequate efficacy or unacceptable safety or tolerability to a tetrabenazine product according to the prescribing physician
Approval duration
1 year